Why the study?
Are plasma 11-dehydroTXB2 levels elevated in patients with ischemic stroke compared to healthy controls?
Are plasma 11-dehydroTXB2 levels elevated in patients with ischemic stroke compared to healthy controls?
Plasma 11-dehydroTXB2 is a reliable biomarker for detecting platelet hyperfunction in patients with ischemic stroke.
Answers are grounded in this paper and cite their sources.
May indicate platelet activation in ischemic stroke; hypothesis-generating and requires prospective validation before clinical use.
The plasma level of 11-dehydrothromboxane B2 (11-dehydroTXB2) is free from artifactual increase during blood sampling, and it can be reliable indicator of TXA2 production in vivo. We have estimated plasma 11-dehydroTXB2 in patients with ischemic stroke. Subjects studied were 29 patients with cerebral thrombosis (62 +/- 9 years old) and 41 healthy controls (61 +/- 7 years old). Plasma 11-dehydroTXB2 and TXB2 were determined by radioimmunoassay. Plasma 11-dehydroTXB2 levels in patients and controls were 5.4 +/- 2.5 and 1.8 +/- 0.9 pg ml, respectively, and the difference was significant (p less than 0.001). Plasma TXB2 also was higher in patients than in controls: 401 +/- 61 vs 311 +/- 51 pg/ml (p less than 0.05). However, the 11-dehydroTXB2 was found to be a more effective parameter to distinguish between stroke patients and controls. Estimation of plasma 11-dehydroTXB2 levels is a reliable method to detect platelet hyperfunction in stroke patients.
No takes yet. Share an insight, caveat, or question.
Satoh et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: